$JNCE Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Jounce Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Jounce Therapeutics, Inc.. Get notifications about new insider transactions in Jounce Therapeutics, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 14 2021 | JNCE | Jounce Therapeutic ... | Third Rock Ventures II, L.P. | 10% Owner | Sell | J | 0.00 | 1,500,000 | 0 | 4,447,829 | 5.9 M to 4.4 M (-25.22 %) |
| Apr 16 2021 | JNCE | Jounce Therapeutic ... | Higgons John Duncan | Director | Sell | S | 10.00 | 200 | 2,000 | 9,713 | 9.9 K to 9.7 K (-2.02 %) |
| Mar 31 2021 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Option Exercise | M | 4.02 | 8,300 | 33,366 | 203,885 | |
| Mar 31 2021 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Option Exercise | M | 4.02 | 100 | 402 | 212,185 | |
| Mar 31 2021 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Option Exercise | M | 4.02 | 5,100 | 20,502 | 212,285 | |
| Mar 31 2021 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Sell | S | 10.09 | 8,300 | 83,747 | 93,585 | 101.9 K to 93.6 K (-8.15 %) |
| Mar 31 2021 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Buy | M | 4.02 | 8,300 | 33,366 | 101,885 | 93.6 K to 101.9 K (+8.87 %) |
| Mar 31 2021 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Sell | S | 10.00 | 100 | 1,000 | 93,585 | 93.7 K to 93.6 K (-0.11 %) |
| Mar 31 2021 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Buy | M | 4.02 | 100 | 402 | 93,685 | 93.6 K to 93.7 K (+0.11 %) |
| Mar 31 2021 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Sell | S | 10.09 | 5,100 | 51,459 | 93,585 | 98.7 K to 93.6 K (-5.17 %) |
| Mar 31 2021 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Buy | M | 4.02 | 5,100 | 20,502 | 98,685 | 93.6 K to 98.7 K (+5.45 %) |
| Mar 17 2021 | JNCE | Jounce Therapeutic ... | Higgons John Duncan | Director | Sell | S | 12.80 | 200 | 2,560 | 9,913 | 10.1 K to 9.9 K (-1.98 %) |
| Mar 15 2021 | JNCE | Jounce Therapeutic ... | Third Rock Ventures II, L.P. | 10% Owner | Sell | J | 0.00 | 1,250,000 | 0 | 6,500,349 | 7.8 M to 6.5 M (-16.13 %) |
| Feb 18 2021 | JNCE | Jounce Therapeutic ... | Higgons John Duncan | Director | Sell | S | 11.78 | 200 | 2,356 | 10,113 | 10.3 K to 10.1 K (-1.94 %) |
| Feb 12 2021 | JNCE | Jounce Therapeutic ... | Salter-Cid Luisa | Director | Option Exercise | A | 12.36 | 31,400 | 388,104 | 31,400 | |
| Feb 03 2021 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Option Exercise | A | 11.89 | 44,500 | 529,105 | 44,500 | |
| Feb 03 2021 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Grant | A | 0.00 | 22,250 | 0 | 93,585 | 71.3 K to 93.6 K (+31.19 %) |
| Feb 03 2021 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Option Exercise | A | 12.67 | 15,000 | 190,050 | 15,000 | |
| Feb 03 2021 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Option Exercise | A | 11.89 | 150,000 | 1,783,500 | 150,000 | |
| Feb 03 2021 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Grant | A | 0.00 | 7,500 | 0 | 222,871 | 215.4 K to 222.9 K (+3.48 %) |
| Feb 03 2021 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Grant | A | 0.00 | 75,000 | 0 | 215,371 | 140.4 K to 215.4 K (+53.43 %) |
| Feb 03 2021 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Option Exercise | A | 11.89 | 44,500 | 529,105 | 44,500 | |
| Feb 03 2021 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Grant | A | 0.00 | 22,250 | 0 | 65,431 | 43.2 K to 65.4 K (+51.53 %) |
| Feb 03 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Option Exercise | A | 11.89 | 53,400 | 634,926 | 53,400 | |
| Feb 03 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Grant | A | 0.00 | 26,700 | 0 | 73,889 | 47.2 K to 73.9 K (+56.58 %) |
| Jan 25 2021 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Option Exercise | M | 0.48 | 33,518 | 16,089 | 665,169 | |
| Jan 25 2021 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Sell | S | 12.06 | 33,518 | 404,227 | 140,371 | 173.9 K to 140.4 K (-19.28 %) |
| Jan 25 2021 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Buy | M | 0.48 | 33,518 | 16,089 | 173,889 | 140.4 K to 173.9 K (+23.88 %) |
| Jan 25 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Option Exercise | M | 6.55 | 5,000 | 32,750 | 55,000 | |
| Jan 25 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Option Exercise | M | 4.40 | 5,000 | 22,000 | 39,500 | |
| Jan 25 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 11.95 | 18,000 | 215,100 | 47,189 | 65.2 K to 47.2 K (-27.61 %) |
| Jan 25 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Buy | M | 6.55 | 5,000 | 32,750 | 65,189 | 60.2 K to 65.2 K (+8.31 %) |
| Jan 25 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Buy | M | 4.40 | 5,000 | 22,000 | 60,189 | 55.2 K to 60.2 K (+9.06 %) |
| Jan 22 2021 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Option Exercise | M | 4.02 | 6,500 | 26,130 | 7,050 | |
| Jan 22 2021 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Sell | S | 12.01 | 6,500 | 78,065 | 71,335 | 77.8 K to 71.3 K (-8.35 %) |
| Jan 22 2021 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Buy | M | 4.02 | 6,500 | 26,130 | 77,835 | 71.3 K to 77.8 K (+9.11 %) |
| Jan 22 2021 | JNCE | Jounce Therapeutic ... | Higgons John Duncan | Director | Sell | S | 11.11 | 200 | 2,222 | 10,313 | 10.5 K to 10.3 K (-1.90 %) |
| Jan 22 2021 | JNCE | Jounce Therapeutic ... | Higgons John Duncan | Director | Sell | S | 12.00 | 1,500 | 18,000 | 10,513 | 12 K to 10.5 K (-12.49 %) |
| Jan 22 2021 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Option Exercise | M | 2.36 | 3,799 | 8,966 | 206,005 | |
| Jan 22 2021 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Option Exercise | M | 2.36 | 3,710 | 8,756 | 209,804 | |
| Jan 22 2021 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Option Exercise | M | 0.74 | 6,775 | 5,014 | 0 | |
| Jan 22 2021 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Option Exercise | M | 0.48 | 3,016 | 1,448 | 0 | |
| Jan 22 2021 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Sell | S | 12.00 | 3,799 | 45,588 | 43,181 | 47 K to 43.2 K (-8.09 %) |
| Jan 22 2021 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Buy | M | 2.36 | 3,799 | 8,966 | 46,980 | 43.2 K to 47 K (+8.80 %) |
| Jan 22 2021 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Sell | S | 10.03 | 10,000 | 100,300 | 43,181 | 53.2 K to 43.2 K (-18.80 %) |
| Jan 22 2021 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Sell | S | 12.03 | 16,201 | 194,898 | 53,181 | 69.4 K to 53.2 K (-23.35 %) |
| Jan 22 2021 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Buy | M | 2.36 | 3,710 | 8,756 | 69,382 | 65.7 K to 69.4 K (+5.65 %) |
| Jan 22 2021 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Buy | M | 0.74 | 6,775 | 5,014 | 65,672 | 58.9 K to 65.7 K (+11.50 %) |
| Jan 22 2021 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Buy | M | 0.48 | 3,016 | 1,448 | 58,897 | 55.9 K to 58.9 K (+5.40 %) |
| Jan 20 2021 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Option Exercise | M | 0.48 | 16,482 | 7,911 | 698,687 | |
| Jan 20 2021 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Option Exercise | M | 0.48 | 40,000 | 19,200 | 715,169 | |
| Jan 20 2021 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Option Exercise | M | 0.48 | 30,000 | 14,400 | 755,169 | |
| Jan 20 2021 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Sell | S | 12.04 | 16,482 | 198,443 | 140,371 | 156.9 K to 140.4 K (-10.51 %) |
| Jan 20 2021 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Buy | M | 0.48 | 16,482 | 7,911 | 156,853 | 140.4 K to 156.9 K (+11.74 %) |
| Jan 20 2021 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Sell | S | 9.59 | 40,000 | 383,600 | 140,371 | 180.4 K to 140.4 K (-22.18 %) |
| Jan 20 2021 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Buy | M | 0.48 | 40,000 | 19,200 | 180,371 | 140.4 K to 180.4 K (+28.50 %) |
| Jan 20 2021 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Sell | S | 8.54 | 30,000 | 256,200 | 140,371 | 170.4 K to 140.4 K (-17.61 %) |
| Jan 20 2021 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Buy | M | 0.48 | 30,000 | 14,400 | 170,371 | 140.4 K to 170.4 K (+21.37 %) |
| Jan 11 2021 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Sell | S | 7.00 | 2,846 | 19,922 | 71,335 | 74.2 K to 71.3 K (-3.84 %) |
| Jan 11 2021 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Sell | S | 6.76 | 2,452 | 16,576 | 74,181 | 76.6 K to 74.2 K (-3.20 %) |
| Jan 11 2021 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Sell | S | 7.00 | 11,816 | 82,712 | 140,371 | 152.2 K to 140.4 K (-7.76 %) |
| Jan 11 2021 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Sell | S | 6.76 | 10,183 | 68,837 | 152,187 | 162.4 K to 152.2 K (-6.27 %) |
| Jan 11 2021 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Sell | S | 7.00 | 3,130 | 21,910 | 55,881 | 59 K to 55.9 K (-5.30 %) |
| Jan 11 2021 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Sell | S | 6.76 | 2,697 | 18,232 | 59,011 | 61.7 K to 59 K (-4.37 %) |
| Jan 11 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 7.00 | 3,340 | 23,380 | 55,189 | 58.5 K to 55.2 K (-5.71 %) |
| Jan 11 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 6.76 | 2,879 | 19,462 | 58,529 | 61.4 K to 58.5 K (-4.69 %) |
| Nov 19 2020 | JNCE | Jounce Therapeutic ... | Third Rock Ventures II, L.P. | 10% Owner | Sell | S | 7.25 | 15,000 | 108,773 | 9,215,349 | 9.2 M to 9.2 M (-0.16 %) |
| Nov 13 2020 | JNCE | Jounce Therapeutic ... | Third Rock Ventures II, L.P. | 10% Owner | Sell | J | 0.00 | 1,000,000 | 0 | 9,230,349 | 10.2 M to 9.2 M (-9.77 %) |
| Sep 16 2020 | JNCE | Jounce Therapeutic ... | Duncan Barbara Gayle | Director | Option Exercise | M | 4.21 | 10,000 | 42,100 | 34,271 | |
| Sep 16 2020 | JNCE | Jounce Therapeutic ... | Duncan Barbara Gayle | Director | Sell | S | 10.50 | 5,000 | 52,500 | 0 | 5 K to 0 (-100.00 %) |
| Sep 16 2020 | JNCE | Jounce Therapeutic ... | Duncan Barbara Gayle | Director | Sell | S | 9.50 | 5,000 | 47,500 | 5,000 | 10 K to 5 K (-50.00 %) |
| Sep 16 2020 | JNCE | Jounce Therapeutic ... | Duncan Barbara Gayle | Director | Buy | M | 4.21 | 10,000 | 42,100 | 10,000 | 0 to 10 K |
| Sep 02 2020 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Sell | S | 8.06 | 7,200 | 58,032 | 61,708 | 68.9 K to 61.7 K (-10.45 %) |
| Aug 18 2020 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Sell | S | 4.71 | 744 | 3,504 | 68,908 | 69.7 K to 68.9 K (-1.07 %) |
| Aug 18 2020 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Sell | S | 4.86 | 454 | 2,206 | 69,652 | 70.1 K to 69.7 K (-0.65 %) |
| Aug 18 2020 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Sell | S | 4.64 | 984 | 4,566 | 70,106 | 71.1 K to 70.1 K (-1.38 %) |
| Aug 18 2020 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Sell | S | 4.71 | 744 | 3,504 | 76,633 | 77.4 K to 76.6 K (-0.96 %) |
| Aug 18 2020 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Sell | S | 4.86 | 454 | 2,206 | 77,377 | 77.8 K to 77.4 K (-0.58 %) |
| Aug 18 2020 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Sell | S | 4.64 | 984 | 4,566 | 77,831 | 78.8 K to 77.8 K (-1.25 %) |
| Aug 18 2020 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 4.71 | 744 | 3,504 | 61,408 | 62.2 K to 61.4 K (-1.20 %) |
| Aug 18 2020 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 4.86 | 454 | 2,206 | 62,152 | 62.6 K to 62.2 K (-0.73 %) |
| Aug 18 2020 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 4.64 | 984 | 4,566 | 62,606 | 63.6 K to 62.6 K (-1.55 %) |
| Jun 29 2020 | JNCE | Jounce Therapeutic ... | TEPPER ROBERT I | Director | Option Exercise | A | 7.58 | 13,550 | 102,709 | 13,550 | |
| Jun 29 2020 | JNCE | Jounce Therapeutic ... | KARSEN PERRY A | Director | Option Exercise | A | 7.58 | 13,550 | 102,709 | 13,550 | |
| Jun 29 2020 | JNCE | Jounce Therapeutic ... | Kamen Robert | Director | Option Exercise | A | 7.58 | 13,550 | 102,709 | 13,550 | |
| Jun 29 2020 | JNCE | Jounce Therapeutic ... | Higgons John Duncan | Director | Option Exercise | A | 7.58 | 13,550 | 102,709 | 13,550 | |
| Jun 29 2020 | JNCE | Jounce Therapeutic ... | Duncan Barbara Gayle | Director | Option Exercise | A | 7.58 | 13,550 | 102,709 | 13,550 | |
| Feb 04 2020 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Option Exercise | A | 6.55 | 44,500 | 291,475 | 44,500 | |
| Feb 04 2020 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Grant | A | 0.00 | 22,250 | 0 | 78,815 | 56.6 K to 78.8 K (+39.34 %) |
| Feb 04 2020 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Option Exercise | A | 6.55 | 60,000 | 393,000 | 60,000 | |
| Feb 04 2020 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Grant | A | 0.00 | 30,000 | 0 | 63,590 | 33.6 K to 63.6 K (+89.31 %) |
| Feb 04 2020 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Option Exercise | A | 6.55 | 150,010 | 982,566 | 150,010 | |
| Feb 04 2020 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Grant | A | 0.00 | 75,010 | 0 | 162,370 | 87.4 K to 162.4 K (+85.86 %) |
| Feb 04 2020 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Option Exercise | A | 6.55 | 53,400 | 349,770 | 53,400 | |
| Feb 04 2020 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Grant | A | 0.00 | 26,700 | 0 | 71,090 | 44.4 K to 71.1 K (+60.15 %) |
| Jan 23 2020 | JNCE | Jounce Therapeutic ... | Iannone Robert | Director | Option Exercise | A | 7.19 | 31,400 | 225,766 | 31,400 | |
| Jan 10 2020 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Sell | S | 7.78 | 2,624 | 20,415 | 44,390 | 47 K to 44.4 K (-5.58 %) |
| Jan 10 2020 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Sell | S | 7.78 | 2,624 | 20,415 | 44,390 | 47 K to 44.4 K (-5.58 %) |
| Jan 10 2020 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Sell | S | 7.78 | 2,624 | 20,415 | 56,565 | 59.2 K to 56.6 K (-4.43 %) |
| Jan 10 2020 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Sell | S | 7.78 | 2,624 | 20,415 | 56,565 | 59.2 K to 56.6 K (-4.43 %) |
| Jan 10 2020 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Sell | S | 7.78 | 7,150 | 55,627 | 87,360 | 94.5 K to 87.4 K (-7.57 %) |
| Jan 10 2020 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Sell | S | 7.78 | 7,150 | 55,627 | 87,360 | 94.5 K to 87.4 K (-7.57 %) |
| Jan 10 2020 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 7.78 | 2,624 | 20,415 | 33,590 | 36.2 K to 33.6 K (-7.25 %) |
| Jan 10 2020 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 7.78 | 2,624 | 20,415 | 33,590 | 36.2 K to 33.6 K (-7.25 %) |
| Jan 08 2020 | JNCE | Jounce Therapeutic ... | Higgons John Duncan | Director | Sell | S | 8.11 | 1,500 | 12,165 | 12,013 | 13.5 K to 12 K (-11.10 %) |
| Dec 26 2019 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Option Exercise | M | 0.48 | 40,000 | 19,200 | 785,169 | |
| Dec 26 2019 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Sell | S | 8.37 | 40,000 | 334,800 | 94,510 | 134.5 K to 94.5 K (-29.74 %) |
| Dec 26 2019 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Buy | M | 0.48 | 40,000 | 19,200 | 134,510 | 94.5 K to 134.5 K (+42.32 %) |
| Aug 16 2019 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 3.92 | 1,018 | 3,991 | 36,214 | 37.2 K to 36.2 K (-2.73 %) |
| Aug 16 2019 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 4.00 | 648 | 2,592 | 37,232 | 37.9 K to 37.2 K (-1.71 %) |
| Aug 16 2019 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 4.10 | 670 | 2,747 | 37,880 | 38.6 K to 37.9 K (-1.74 %) |
| Aug 16 2019 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Sell | S | 3.92 | 1,018 | 3,991 | 59,189 | 60.2 K to 59.2 K (-1.69 %) |
| Aug 16 2019 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Sell | S | 4.00 | 648 | 2,592 | 60,207 | 60.9 K to 60.2 K (-1.06 %) |
| Aug 16 2019 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Sell | S | 4.10 | 670 | 2,747 | 60,855 | 61.5 K to 60.9 K (-1.09 %) |
| Aug 16 2019 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Sell | S | 3.92 | 1,018 | 3,991 | 47,014 | 48 K to 47 K (-2.12 %) |
| Aug 16 2019 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Sell | S | 4.00 | 648 | 2,592 | 48,032 | 48.7 K to 48 K (-1.33 %) |
| Aug 16 2019 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Sell | S | 4.10 | 670 | 2,747 | 48,680 | 49.4 K to 48.7 K (-1.36 %) |
| Jun 13 2019 | JNCE | Jounce Therapeutic ... | TEPPER ROBERT I | Director | Option Exercise | A | 4.46 | 15,700 | 70,022 | 15,700 | |
| Jun 13 2019 | JNCE | Jounce Therapeutic ... | Diaz Luis | Director | Option Exercise | A | 4.46 | 15,700 | 70,022 | 15,700 | |
| Jun 13 2019 | JNCE | Jounce Therapeutic ... | Duncan Barbara Gayle | Director | Option Exercise | A | 4.46 | 15,700 | 70,022 | 15,700 | |
| Jun 13 2019 | JNCE | Jounce Therapeutic ... | Kamen Robert | Director | Option Exercise | A | 4.46 | 15,700 | 70,022 | 15,700 | |
| Jun 13 2019 | JNCE | Jounce Therapeutic ... | Pfeffer Cary | Director | Option Exercise | A | 4.46 | 15,700 | 70,022 | 15,700 | |
| Jun 13 2019 | JNCE | Jounce Therapeutic ... | KARSEN PERRY A | Director | Option Exercise | A | 4.46 | 15,700 | 70,022 | 15,700 | |
| Jun 13 2019 | JNCE | Jounce Therapeutic ... | Higgons John Duncan | Director | Option Exercise | A | 4.46 | 15,700 | 70,022 | 15,700 | |
| Feb 05 2019 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Option Exercise | A | 4.40 | 44,500 | 195,800 | 44,500 | |
| Feb 05 2019 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Grant | A | 0.00 | 22,250 | 0 | 61,525 | 39.3 K to 61.5 K (+56.65 %) |
| Feb 05 2019 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Option Exercise | A | 4.40 | 44,500 | 195,800 | 44,500 | |
| Feb 05 2019 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Grant | A | 0.00 | 22,250 | 0 | 38,550 | 16.3 K to 38.6 K (+136.50 %) |
| Feb 05 2019 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Option Exercise | A | 4.40 | 44,500 | 195,800 | 44,500 | |
| Feb 05 2019 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Grant | A | 0.00 | 22,250 | 0 | 49,350 | 27.1 K to 49.4 K (+82.10 %) |
| Feb 05 2019 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Option Exercise | A | 4.40 | 125,010 | 550,044 | 125,010 | |
| Feb 05 2019 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Grant | A | 0.00 | 62,510 | 0 | 94,510 | 32 K to 94.5 K (+195.34 %) |
| Sep 07 2018 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Option Exercise | M | 0.48 | 32,000 | 15,360 | 825,169 | |
| Sep 07 2018 | JNCE | Jounce Therapeutic ... | MURRAY RICHARD /CA/ | CEO and President | Buy | M | 0.48 | 32,000 | 15,360 | 32,000 | 0 to 32 K |
| Aug 28 2018 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Option Exercise | M | 2.36 | 12,700 | 29,972 | 213,514 | |
| Aug 28 2018 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Buy | M | 2.36 | 12,700 | 29,972 | 27,100 | 14.4 K to 27.1 K (+88.19 %) |
| Aug 15 2018 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Grant | A | 0.00 | 14,400 | 0 | 39,275 | 24.9 K to 39.3 K (+57.89 %) |
| Aug 15 2018 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Grant | A | 0.00 | 14,400 | 0 | 16,300 | 1.9 K to 16.3 K (+757.89 %) |
| Aug 15 2018 | JNCE | Jounce Therapeutic ... | Drapkin Kimberlee C | CFO and Treasurer | Grant | A | 0.00 | 14,400 | 0 | 14,400 | 0 to 14.4 K |
| Jun 21 2018 | JNCE | Jounce Therapeutic ... | Kamen Robert | Director | Option Exercise | A | 7.92 | 13,550 | 107,316 | 13,550 | |
| Jun 21 2018 | JNCE | Jounce Therapeutic ... | KARSEN PERRY A | Director | Option Exercise | A | 7.92 | 13,550 | 107,316 | 13,550 | |
| Jun 21 2018 | JNCE | Jounce Therapeutic ... | Higgons John Duncan | Director | Option Exercise | A | 7.92 | 13,550 | 107,316 | 13,550 | |
| Jun 21 2018 | JNCE | Jounce Therapeutic ... | Duncan Barbara Gayle | Director | Option Exercise | A | 7.92 | 13,550 | 107,316 | 13,550 | |
| Jun 21 2018 | JNCE | Jounce Therapeutic ... | Diaz Luis | Director | Option Exercise | A | 7.92 | 10,163 | 80,491 | 10,163 | |
| Jun 21 2018 | JNCE | Jounce Therapeutic ... | TEPPER ROBERT I | Director | Option Exercise | A | 7.92 | 13,550 | 107,316 | 13,550 | |
| Jun 21 2018 | JNCE | Jounce Therapeutic ... | Pfeffer Cary | Director | Option Exercise | A | 7.92 | 13,550 | 107,316 | 13,550 | |
| Jun 18 2018 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Buy | P | 7.84 | 1,900 | 14,896 | 1,900 | 0 to 1.9 K |
| Jun 12 2018 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Option Exercise | M | 4.02 | 24,875 | 99,998 | 217,385 | |
| Jun 12 2018 | JNCE | Jounce Therapeutic ... | Trehu Elizabeth | Chief Medical Offic ... | Buy | M | 4.02 | 24,875 | 99,998 | 24,875 | 0 to 24.9 K |
| Mar 19 2018 | JNCE | Jounce Therapeutic ... | Duncan Barbara Gayle | Director | Option Exercise | M | 4.21 | 2,000 | 8,420 | 44,271 |